Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages mdw615
Publisher
Oxford University Press (OUP)
Online
2016-11-10
DOI
10.1093/annonc/mdw615
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tricking the balance: NK cells in anti-cancer immunity
- (2017) Jens Pahl et al. IMMUNOBIOLOGY
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
- (2016) G. An et al. BLOOD
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Myeloid-derived suppressor cells: The green light for myeloma immune escape
- (2016) Ehsan Malek et al. BLOOD REVIEWS
- IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
- (2016) Philippos Perimenis et al. BMC CANCER
- Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
- (2016) Baiteng Zhao et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tumor microenvironment and cancer therapy resistance
- (2016) Yu Sun CANCER LETTERS
- Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
- (2016) J. Baselga et al. CLINICAL CANCER RESEARCH
- CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies
- (2016) CJ Turtle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program
- (2016) P.L. Zinzani et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapy advances in uro-genital malignancies
- (2016) Raffaele Ratta et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Monitoring immune responses in the tumor microenvironment
- (2016) Jennifer A Wargo et al. CURRENT OPINION IN IMMUNOLOGY
- Antibody drug conjugates
- (2016) Edith Borcoman et al. CURRENT OPINION IN ONCOLOGY
- Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
- (2016) Eri Matsuki et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
- (2016) Lavinia Spain et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors
- (2016) Julius Strauss et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma
- (2016) Nabila Bennani-Baiti et al. Expert Review of Clinical Immunology
- Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines
- (2016) T. J. Vreeland et al. Expert Review of Clinical Immunology
- Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions
- (2016) Matthew Zibelman et al. Immunotherapy
- Roles of regulatory T cells in cancer immunity
- (2016) Yoshiko Takeuchi et al. INTERNATIONAL IMMUNOLOGY
- Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1)vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer
- (2016) Sung-Bae Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
- (2016) Teofila Seremet et al. Journal of Translational Medicine
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Immunological off-target effects of imatinib
- (2016) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
- (2016) Maria I. Carlo et al. Nature Reviews Urology
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
- (2016) L. Gandolfi et al. ONCOLOGIST
- Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia
- (2016) Constantine S. Tam et al. SEMINARS IN ONCOLOGY
- TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
- (2016) B. V. Park et al. Cancer Discovery
- Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
- (2016) K. Newick et al. Cancer Immunology Research
- Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
- (2015) Meagan S. Barbee et al. ANNALS OF PHARMACOTHERAPY
- Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+lymphoid malignancies
- (2015) Andrew W. Roberts et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors
- (2015) Anja Derer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Emerging therapeutic targets in bladder cancer
- (2015) Benedito A. Carneiro et al. CANCER TREATMENT REVIEWS
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer
- (2015) V. K. Anagnostou et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors with radiotherapy and locoregional treatment
- (2015) Angela Esposito et al. CURRENT OPINION IN ONCOLOGY
- Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment
- (2015) Farhadul Islam et al. EXPERIMENTAL CELL RESEARCH
- Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia
- (2015) Alla Dolnikov et al. EXPERIMENTAL HEMATOLOGY
- Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond
- (2015) Yin Wu et al. Expert Review of Anticancer Therapy
- Checkpoint inhibitors in bladder and renal cancers: results and perspectives
- (2015) Fouad Aoun et al. Immunotherapy
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Cancer immunotherapy: Strategies for personalization and combinatorial approaches
- (2015) Vishwanath Sathyanarayanan et al. Molecular Oncology
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
- (2015) K Cao et al. ONCOGENE
- A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
- (2015) Monica Cojoc et al. SEMINARS IN CANCER BIOLOGY
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors
- (2015) Steven A. Feldman et al. SEMINARS IN ONCOLOGY
- NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
- (2015) Wei Wang Frontiers in Immunology
- Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics
- (2015) Benjamin Bonavida et al. Redox Biology
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Mechanisms of Resistance Against Cancer Therapeutic Drugs
- (2014) Shailja Chatterjee et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Cancer stem cells - important players in tumor therapy resistance
- (2014) Selcuk Colak et al. FEBS Journal
- B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look
- (2014) Jenessa B. Smith et al. GYNECOLOGIC ONCOLOGY
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
- (2014) Michele Ardolino et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Modulation of the Tumor Cell Phenotype by IFN- Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes
- (2014) K. Hallermalm et al. JOURNAL OF IMMUNOLOGY
- Role of TGF-β Signaling in Generation of CD39+CD73+Myeloid Cells in Tumors
- (2014) Sergey V. Ryzhov et al. JOURNAL OF IMMUNOLOGY
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-17 Facilitates the Immune Suppressor Capacity of High-Grade Glioma-Derived CD4 (+) CD25 (+) Foxp3 (+) T Cells Via Releasing Transforming Growth Factor Beta
- (2014) H. Liang et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
- (2013) Matthew D. Vesely et al. Annals of the New York Academy of Sciences
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- The use of endogenous T cells for adoptive transfer
- (2013) Cassian Yee IMMUNOLOGICAL REVIEWS
- Exploiting the curative potential of adoptive T-cell therapy for cancer
- (2013) Christian S. Hinrichs et al. IMMUNOLOGICAL REVIEWS
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells
- (2013) Hirotomo Harimoto et al. IMMUNOLOGY AND CELL BIOLOGY
- Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF- 1
- (2013) M. Hasmim et al. JOURNAL OF IMMUNOLOGY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
- (2013) L. M. Coussens et al. SCIENCE
- Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
- (2013) Robert Wesolowski et al. Journal for ImmunoTherapy of Cancer
- Therapeutic Antibodies Against Cancer
- (2012) Mark J. Adler et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- Strategies for Enhancing Vaccine-Induced CTL Antitumor Immune Responses
- (2012) Xin Yong et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- Evaluation of Current Cancer Immunotherapy
- (2011) Christopher S. Hourigan et al. CANCER JOURNAL
- Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
- (2011) P. B. Olkhanud et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
- (2011) Asis Palazón et al. CLINICAL CANCER RESEARCH
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis
- (2011) Laura M. Hix et al. PLoS One
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
- (2010) Karl S Peggs et al. Expert Review of Anticancer Therapy
- Warburg phenotype in renal cell carcinoma: High expression of glucose-transporter 1 (GLUT-1) correlates with low CD8+ T-cell infiltration in the tumor
- (2010) Katrin Singer et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
- (2010) R Shimizu et al. LEUKEMIA
- A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells
- (2010) Mario I. Vega et al. LEUKEMIA & LYMPHOMA
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy
- (2010) Arvind Chhabra VACCINE
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
- (2009) C Alfaro et al. BRITISH JOURNAL OF CANCER
- Inhibition of Superoxide Generation upon T-Cell Receptor Engagement Rescues Mart-127-35-Reactive T Cells from Activation-Induced Cell Death
- (2009) H. Norell et al. CANCER RESEARCH
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Adoptive cell therapy for the treatment of patients with metastatic melanoma
- (2009) Steven A Rosenberg et al. CURRENT OPINION IN IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
- (2008) Barbara Pro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Targeting Cell Death in Tumors by Activating Caspases
- (2008) A. Clark et al. CURRENT CANCER DRUG TARGETS
- Nuclear Factor-κB Activation: From Bench to Bedside
- (2008) Gautam Sethi et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
- (2008) J. B. Swann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started